Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK6 | Q16659 | 12/20 | 0.66 |
| ▸ | GSK3A | P49840 | 3/20 | 0.53 |
| ▸ | GSK3B | P49841 | 3/20 | 0.53 |
| ▸ | EIF2AK4 | Q9P2K8 | 3/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16012342 | 0.93 | MAPK6 (0.66) | MAPK6GSK3AGSK3BEIF2AK4AURKA | |
| SCHEMBL16012031 | 0.92 | MAPK6 (0.76) | MAPK6GSK3AGSK3BEIF2AK4AURKA | |
| SCHEMBL18830309 | 0.92 | MAPK6 (0.76) | MAPK6GSK3AGSK3BEIF2AK4AURKA | |
| SCHEMBL16012236 | 0.92 | MAPK6 (0.76) | MAPK6GSK3AGSK3BEIF2AK4AURKA | |
| SCHEMBL18830385 | 0.92 | MAPK6 (0.76) | MAPK6GSK3AGSK3BEIF2AK4AURKA | |
| SCHEMBL16022263 | 0.91 | MAPK6 (0.61) | MAPK6GSK3AGSK3BEIF2AK4AURKA | |
| SCHEMBL16012229 | 0.90 | MAPK6 (0.66) | MAPK6GSK3AGSK3BEIF2AK4AURKA | |
| SCHEMBL17446333 | 0.88 | MAPK6 (0.61) | MAPK6GSK3AGSK3BEIF2AK4AURKA | |
| SCHEMBL16012444 | 0.88 | MAPK6 (0.61) | MAPK6GSK3AGSK3BEIF2AK4AURKA | |
| SCHEMBL16011971 | 0.88 | MAPK6 (0.65) | MAPK6GSK3AGSK3BEIF2AK4AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014135244-A1 | TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | MERCK PATENT GMBH (DE) | 2014-09-12 | — | — | WO | disclosed |